{
  "docId": "019de076-3901-734c-833f-b5b0e2d3aa41",
  "docSlug": "e86c5f257c7f518e1f9c16c922f96c7d",
  "documentTitle": "Exscientia | Investor Presentation Deck | 76 slides",
  "authorId": "exscientia",
  "authorName": "Exscientia",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 71,
  "pageCount": 76,
  "prevPage": 70,
  "nextPage": 72,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "The slide demonstrates efficacy and synergy in vivo for a drug candidate ('565) in DLBCL models.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-3901-734c-833f-b5b0e2d3aa41/71",
  "deckHref": "/decks/019de076-3901-734c-833f-b5b0e2d3aa41",
  "deckJsonHref": "/decks/019de076-3901-734c-833f-b5b0e2d3aa41.json",
  "deckAnchorHref": "/decks/019de076-3901-734c-833f-b5b0e2d3aa41#slide-71",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.4,
        "x": 0.55,
        "y": 0.208
      },
      "kind": "chart",
      "text": "‘565 ± ibrutinib in TMD8 xenograft model",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4a19766a-ebb1-44e1-abc9-ec8080d813fe",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.4,
        "x": 0.05,
        "y": 0.208
      },
      "kind": "chart",
      "text": "‘565 ± ibrutinib in OCI-Ly10 xenograft model",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c6395d98-b2ce-47e5-84c8-61ba35a60307",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.4,
        "x": 0.05,
        "y": 0.67
      },
      "kind": "list",
      "text": "OCI-Ly10 cells are sensitive to both MALT1i and ibrutinib in vitro; Administration of ‘565 as a single agent showed tumour growth regression; Synergistic tumour growth observed when 10 mpk ‘565 was combined with ibrutinib",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "918668f2-60dc-4c03-a970-0772113118ed",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.4,
        "x": 0.55,
        "y": 0.67
      },
      "kind": "list",
      "text": "TMD8 DLBCL cells are sensitive to both MALT1i and ibrutinib in vitro, however, standalone administration of ibrutinib showed no activity in vivo; Significant synergistic efficacy was observed when ‘565 was combined with ibrutinib in the study; ‘565 was well tolerated",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ac44d757-1284-43bc-9709-57ff989e8124",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.6,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Payne et al. ESMO, 2023; OCI-Ly10 xenograft model: CD79A mutant; TMD8 xenograft model: CD79B mutant",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e21d396e-76a1-4586-bf7f-d7927d1d187f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.7,
        "x": 0.05,
        "y": 0.12
      },
      "kind": "title",
      "text": "Single agent and synergistic effects seen in DLBCL xenograft models",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fe7cb83c-18ad-4433-9230-a42657693e39",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "‘565 inhibits DLBCL tumour model growth in vivo",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "91ac84bd-65bb-4488-9408-f2040c4bb885",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "9324710d-7ecb-4c82-bf4f-7e27843ccf4c",
      "evidence": "chart/line: ‘565 ± ibrutinib in OCI-Ly10 xenograft model and chart/line: ‘565 ± ibrutinib in TMD8 xenograft model",
      "confidence": 0.6
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}